TCTR20210322002已完成4 期
Effect of empagliflozin/linagliptin on oxidative stress markers in chronic kidney patient with type 2 diabetes stage 3: A randomized, open label controlled trial
/A0 个研究点目标入组 48 人开始时间: 2021年3月22日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 N/A (No limit)（—）
- 性别
- All
入选标准
- •eGFR 30-59 ml/min/1.73m2
- •T2DM HbA1c 7-10%
- •No treatment adjusted with anti-HT within 1 months
排除标准
- •T1DM or secondary diabetes
- •History of diabetic ketoacidosis
- •Current history of urinary and genital tract infection
- •Pancreatic and active liver disease
- •proliferative diabetic retinopathy
- •Recent smoking < 6 month
- •Herbal medicine use
- •Active infection
- •Active malignancy
- •Alzheimer disease
- •Breast feeding
研究者
相似试验
已完成
不适用
Effects of Empagliflozin in Reducing Oxidative Stress After Kidney TransplantationKidney Transplant ComplicationsNCT04918407Shahid Beheshti University of Medical Sciences40
已完成
不适用
Evaluation of anti oxidative effect of linagliptin on type 2 diabetic patients.type2 diabetesJPRN-UMIN000015308linagliptin study group30
招募中
3 期
Evaluation effect of Empagliflozin in psychiatric disordersIRCT20180404039187N9Tabriz University of Medical Sciences40
已完成
2 期
The Effect Effect of Empagliflozin on Oxidative Stress in Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT02890745Henrik Enghusen Poulsen31
进行中（未招募）
1 期
Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology and Metabolic Control in Patients with Type 2 Diabetes Mellitus on Stable Metformin TreatmentType 2 Diabetes MellitusEUCTR2014-004895-48-DEProfil Institut für Stoffwechselforschung GmbH